EAP-Derived Monoclonal Antibodies for Phenotyping Immune Cells of Animal Model of Disease

EAP 衍生单克隆抗体用于疾病动物模型免疫细胞表型分析

• 批准号: 10933282
• 负责人: MARK GEISBERG
• 金额: $ 75万
• 依托单位: SILVER LAKE RESEARCH CORPORATION
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10933282
• 关键词: Animal Disease Models; Antibodies; Antibody Specificity; Biological Assay; Cells; Communities; Disease model; Homologous Gene; Immune; Industrialization; Inflammation; Label; Monoclonal Antibodies; Phase; Phenotype; Protocols documentation; Reagent; Research; Silver; Testing; Validation; cross reactivity; usability

Silver Lake proposes to fully characterize mAb against 6 targets produced in their three concurrent Phase 1 projects that are relevant in models of disease and inflammation, determine their usability in multiple assay types, develop user protocols for each assay type and mAb, produce quality-controlled reagents, produce multiple conjugates for each mAb, and make all reagents available for the research community.

Silver Lake提议完全表征MAB的三个并发1期项目中产生的6个目标，这些目标与疾病和炎症模型相关，确定其在多种测定类型中的可用性，为每种测定类型开发用户协议，并MAB，生成质量控制的复发，为每个MAB生成多个共与研究群体，并为研究群体提供可用性。